112 related articles for article (PubMed ID: 7808178)
1. [Rhinitis medicamentosa, an increasing problem. Do nose drops adversely affect bacterial infections?].
Wilhelmson B
Lakartidningen; 1994 Dec; 91(49):4635-6. PubMed ID: 7808178
[No Abstract] [Full Text] [Related]
2. [Ultrastructural changes in human nasal mucosa in rhinitis medicamentosa].
Knipping S; Holzhausen HJ; Riederer A; Bloching M
HNO; 2006 Oct; 54(10):742-8. PubMed ID: 16477462
[TBL] [Abstract][Full Text] [Related]
3. ["Of snakes and crocodiles": central side effects of nose drops and facts about rhinitis medicamentosa].
Bielenberg J
Kinderkrankenschwester; 2011 Oct; 30(10):406-8. PubMed ID: 22029138
[No Abstract] [Full Text] [Related]
4. [Nasal decongestants and eye drops: keep out of children's reach!].
Poulin-Chartrand S
Perspect Infirm; 2013; 10(2):63. PubMed ID: 23539872
[No Abstract] [Full Text] [Related]
5. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity.
Graf P
Rhinology; 1996 Mar; 34(1):9-13. PubMed ID: 8739860
[TBL] [Abstract][Full Text] [Related]
6. [Rhinitis medicamentosa in cytological assessment of the nasal mucosa].
Tarchalska B; Gotlib T; Samoliński B
Pol Merkur Lekarski; 2005 Sep; 19(111):288-90. PubMed ID: 16358845
[TBL] [Abstract][Full Text] [Related]
7. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment.
Graf P; Hallén H
ORL J Otorhinolaryngol Relat Spec; 1997; 59(1):39-44. PubMed ID: 9104748
[TBL] [Abstract][Full Text] [Related]
8. Is oxymetazoline really safe for middle ear use.
Seidman MD
Laryngoscope; 2005 Jul; 115(7):1321-3; author reply 1323. PubMed ID: 15995530
[No Abstract] [Full Text] [Related]
9. [Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].
Dorn M; Hofmann W; Knick E
HNO; 2003 Oct; 51(10):794-9. PubMed ID: 14523532
[TBL] [Abstract][Full Text] [Related]
10. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal.
Graf PM; Hallén H
Am J Rhinol; 1997; 11(1):67-72. PubMed ID: 9065350
[TBL] [Abstract][Full Text] [Related]
11. CNS reactions to nose drops in small children.
Söderman P; Sahlberg D; Wiholm BE
Lancet; 1984 Mar; 1(8376):573. PubMed ID: 6142294
[No Abstract] [Full Text] [Related]
12. [Nose drops--therapeutic effects and applications].
Reiss M; Reiss G
Praxis (Bern 1994); 2001 Jun; 90(25-26):1145-7. PubMed ID: 11469055
[TBL] [Abstract][Full Text] [Related]
13. [Xylometazoline (Otrivin) in acute rhinitis. A comparative study between pipette- and metered-dose aerosol applications].
Myklebust G; Sandvik L; Frostad AB
Tidsskr Nor Laegeforen; 1984 Oct; 104(29):2024-5. PubMed ID: 6150564
[No Abstract] [Full Text] [Related]
14. Nose drops induce vasomotion in the microcirculation of the sinus mucosa of the rabbit.
Bende M; Arfors KE; Intaglietta M
ORL J Otorhinolaryngol Relat Spec; 1993; 55(2):110-3. PubMed ID: 7680443
[TBL] [Abstract][Full Text] [Related]
15. [Overuse of nasal adrenergic agents--time for a warning, again!].
Holmström M
Lakartidningen; 2007 Feb 21-27; 104(8):612. PubMed ID: 17396466
[No Abstract] [Full Text] [Related]
16. Treatment with xylometazoline (Otrivin) nosedrops over a six-week period.
Petruson B
Rhinology; 1981 Sep; 19(3):167-72. PubMed ID: 6171024
[TBL] [Abstract][Full Text] [Related]
17. Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: an experimental study.
Tas A; Yagiz R; Yalcin O; Uzun C; Huseyinova G; Adali MK; Karasalihoglu AR
Otolaryngol Head Neck Surg; 2005 Apr; 132(4):608-12. PubMed ID: 15806055
[TBL] [Abstract][Full Text] [Related]
18. Use of anticholinergics to treat bradycardia caused by alpha1-adrenergic agonist overdose is not safe.
Sprung J; Alhaddad ST
J Clin Anesth; 1996 Aug; 8(5):426-7. PubMed ID: 8832455
[No Abstract] [Full Text] [Related]
19. Paranoid psychosis induced by oxymetazoline nasal spray.
Ticoll B; Shugar G
CMAJ; 1994 Feb; 150(3):375-6. PubMed ID: 8293377
[No Abstract] [Full Text] [Related]
20. Intranasal 3% Tetracaine Plus 0.05% Oxymetazoline in the Management of Status Migrainosus.
Darsey M; Kyros T; Wang V; Rizzoli PB
Headache; 2020 Feb; 60(2):471-472. PubMed ID: 31919839
[No Abstract] [Full Text] [Related]
[Next] [New Search]
